Pharming Group (NASDAQ:PHAR) Shares Gap Down to $9.43

Posted by Faye Duncan on May 24th, 2024

Pharming Group (NASDAQ:PHAR – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $9.43, but opened at $9.00. Pharming Group shares last traded at $9.00, with a volume of 1,898 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 14th.

Get Our Latest Report on PHAR

Pharming Group Stock Down 2.7 %

The firm’s 50 day moving average is $10.19 and its 200 day moving average is $11.19.

Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $71.83 million. Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. As a group, analysts anticipate that Pharming Group will post -0.03 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new position in Pharming Group (NASDAQ:PHAR – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.